South Korea
Kanaph Therapeutics and IMbiologics launched successful offerings in the IPO-scarce Korean market in the first quarter, as investors become more selective in their targets.
In an interview with Scrip, Samsung Bioepis’ VP and Innovation Project Lead talks about the newly launched innovation project as well as the firm's strategies and goals in ADCs and other novel therapeutics.
South Korea's government is expanding initiatives to attract clinical trials, foreign pharma investment and partnerships as it looks to support domestic firms' R&D and international expansion ambitions.
NextGate Partners’ managing partner shares his views on the biopharma investment and dealmaking environment in South Korea, along with the particular strengths of companies in the country and R&D areas of focus for this year.
Aside from logging generally solid earnings, South Korean pharma firms Yuhan, Hanmi and SK Biopharmaceuticals disclosed updated R&D strategies involving obesity treatments and new modalities.
SK bioscience jumps into RSV preventive antibody space through new Gates alliance.
PharmAbcine founder shares views on current lack of post-delisting protections for technology companies in South Korea, proposing special regulations to safeguard expertise and assets for a certain period.
AriBio reaches an exclusive global out-licensing deal with Restari for its next generation PDE-5 inhibitor.
A CEPI-supported partnership between MSD Hilleman and SK bioscience aims to improve Ebola vaccine manufacturing and supply.
Amid Pfizer’s acquisition of Metsera and Hanmi’s novel contender moving to the approval stage, South Korean obesity assets are poised to attract more interest from global pharma firms and investors.
Alteogen’s new CEO shares his dynamic five years with the Korean biotech which led to its transformation into a global commercial stage biotech with a potential stable revenue base.
The Korean biopharma industry in 2025 was marked by some major deals involving smaller companies, while the improving investment climate could see further activity in selected areas in 2026.
Despite recent setbacks in the field, big pharma still appears to have faith in the tau approach to Alzheimer's, as evidenced by Sanofi's new $1bn-plus deal with Korean venture ADEL for an early stage candidate.
Hanmi Pharm Group announces new mid-term strategy including expansion of its obesity focus to aging with goal of more than doubling revenue by 2030 and becoming a true global player.
The success of AimedBio’s IPO may indicate investors are returning to the South Korean biopharma sector amid a series of large global out-licensing deals by domestic ventures and the strong performance of some recent biotech debutants on Kosdaq.
Hanmi is acquiring the Toronto-based biotech, Aptose, following positive early data of its lead asset tuspetinib in AML. The deal also gives Hanmi a strategic foothold in North America and marks another oncology-focused acquisition by a Korean pharma firm.
Korean biopharma firms are bracing for the impending US tariffs on pharmaceuticals and taking different approaches to tackle the situation.
Scrip brings you its quarterly roundup of earnings and other key developments in the Korean pharma sector including the acquisition of Taxotere by Boryung and the progress of Hanmi’s obesity contender.
South Korea’s two biosimilars giants have laid out differing strategies to pursue innovative drug R&D, although both are positioning ADCs as a core focus.
Alteogen's preparations to move its stock listing, ABL Bio's injection of funds into its US subsidiary to progress clinical trials and Ensol's plans for a Phase III trial of its osteoarthritis contender are among key recent developments in Korean biotech.